Adaptive Biotechnologies
ADPT
111 hedge funds and large institutions have $3.74B invested in Adaptive Biotechnologies in 2019 Q2 according to their latest regulatory filings, with 111 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
64.67% more ownership
Funds ownership: 0% → 64.67% (+65%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$1.7B |
| 2 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$768M |
| 3 |
SIG
Senator Investment Group
New York
|
+$227M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$51.6M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$39.9M |
Top Sellers
ADPT Hedge Fund Activity: Q2 2019 in Review
111 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q2 2019, worth a combined $3.74B.
Buyers outnumbered sellers: 111 funds opened new ADPT positions and 0 closed out — a net gain of 111 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $1.7B.
- 111 institutional investors held Adaptive Biotechnologies (ADPT) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $3.74B of Adaptive Biotechnologies stock for Q2 2019.
- 111 funds opened new Adaptive Biotechnologies positions in Q2 2019 and 0 closed out, a net change of +111 holders.
- The largest Adaptive Biotechnologies buyer in Q2 2019 was Viking Global Investors, an estimated $1.7B added.
Based on aggregated 13F filings for Q2 2019.